Skip header and navigation

Refine By

9 records – page 1 of 1.

[Decreasing cardiovascular morbidity: how to improve adherence to the treatment in the translational era].

https://arctichealth.org/en/permalink/ahliterature303944
Source
Ter Arkh. 2020 Oct 14; 92(9):49-53
Publication Type
Journal Article
Date
Oct-14-2020
Author
I V Zhirov
Author Affiliation
National Medical Research Center for Cardiology.
Source
Ter Arkh. 2020 Oct 14; 92(9):49-53
Date
Oct-14-2020
Language
Russian
Publication Type
Journal Article
Keywords
Aspirin
Cardiovascular Diseases - epidemiology - prevention & control
Humans
Morbidity
Russia - epidemiology
Tablets, Enteric-Coated
Abstract
Cardiovascular diseases are the main drivers of the morbidity and mortality in Russian Federation. We briefly discussed the poor adherence of the patients and outlined the solutions of this problem.
????????-?????????? ??????????? ???????? ??????? ???????? ?????????? ? ?????????????? ????? ????????? ?????????? ?????????. ?????? ??????? ????????? ? ???????????? ??????????? ?????????????? ????????? ???????, ???? ????????? ??????? ?????? ????????.
PubMed ID
33346431 View in PubMed
Less detail

[Development of an optimal enteric-soluble film-forming composite based on acetylphthalylcellulose for coating tablets in a fluidized bed]

https://arctichealth.org/en/permalink/ahliterature8886
Source
Farm Zh. 1975 Mar-Apr;(2):47-51
Publication Type
Article

[Development of the optimal film-forming composition based on ethylcellulose for the protective coating of tablets on a fluidized bed]

https://arctichealth.org/en/permalink/ahliterature13216
Source
Farm Zh. 1976 Mar-Apr;(2):65-8
Publication Type
Article

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.

https://arctichealth.org/en/permalink/ahliterature215237
Source
Br J Clin Pharmacol. 1995 May;39(5):511-8
Publication Type
Article
Date
May-1995
Author
M. Chang
G. Tybring
M L Dahl
E. Götharson
M. Sagar
R. Seensalu
L. Bertilsson
Author Affiliation
Department of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Sweden.
Source
Br J Clin Pharmacol. 1995 May;39(5):511-8
Date
May-1995
Language
English
Publication Type
Article
Keywords
2-Pyridinylmethylsulfinylbenzimidazoles
Administration, Oral
Adult
Aryl Hydrocarbon Hydroxylases
Chromatography, High Pressure Liquid
Cohort Studies
Cytochrome P-450 Enzyme System - genetics - metabolism
Female
Gastrins - blood
Heterozygote
Humans
Male
Mixed Function Oxygenases - genetics - metabolism
Omeprazole - administration & dosage - analogs & derivatives - blood - pharmacokinetics - pharmacology
Phenotype
Polymorphism, Genetic
Sweden
Tablets, Enteric-Coated
Abstract
1. Fourteen healthy Swedish Caucasian subjects were given 20 mg of omeprazole orally each morning for 8 days. The subjects included five poor metabolisers (PM) of S-mephenytoin, four heterozygous extensive metabolisers (hetEM) and five subjects with a very rapid metabolism (rapidEM). 2. After the first dose, the relative mean areas under the plasma concentration vs time curve (AUC) of omeprazole in rapidEM, hetEM and PM were 1:3.7:20 (all different, P
Notes
Cites: Clin Pharmacol Ther. 1993 May;53(5):608-108338569
Cites: Pharmacogenetics. 1992 Feb;2(1):32-71302041
Cites: J Pharmacol Exp Ther. 1993 Jul;266(1):52-98331574
Cites: Arch Biochem Biophys. 1993 Oct;306(1):240-58215410
Cites: Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11825-97903454
Cites: Biochemistry. 1994 Feb 22;33(7):1743-528110777
Cites: J Biol Chem. 1994 Jun 3;269(22):15419-228195181
Cites: Ther Drug Monit. 1994 Apr;16(2):214-58009572
Cites: Br J Clin Pharmacol. 1993 Dec;36(6):521-3012959268
Cites: Scand J Gastroenterol. 1975;10(3):273-71138329
Cites: Nature. 1981 Mar 12;290(5802):159-616259537
Cites: J Pharmacol Exp Ther. 1981 Jul;218(1):193-97241378
Cites: Gut. 1983 Apr;24(4):270-66832622
Cites: Gastroenterology. 1984 Nov;87(5):1030-46479529
Cites: J Chromatogr. 1984 Aug 10;309(2):347-566480786
Cites: Clin Pharmacol Ther. 1984 Dec;36(6):773-806499356
Cites: Br J Clin Pharmacol. 1990 May;29(5):557-632350532
Cites: Lancet. 1990 Sep 1;336(8714):529-321975039
Cites: Ther Drug Monit. 1990 Jul;12(4):415-62396316
Cites: Br J Clin Pharmacol. 1991 Mar;31(3):350-22054275
Cites: Br J Clin Pharmacol. 1991 Jun;31(6):689-921867963
Cites: DNA Cell Biol. 1991 Oct;10(8):545-581681816
Cites: Clin Pharmacol Ther. 1992 Jan;51(1):12-71346258
Cites: Clin Pharmacol Ther. 1992 Apr;51(4):388-971345344
Cites: Gastroenterology. 1992 Sep;103(3):913-81499942
Cites: J Pharmacol Exp Ther. 1992 Sep;262(3):1195-2021527724
Cites: Lancet. 1993 Jan 2;341(8836):638093319
Cites: Pharmacogenetics. 1991 Oct;1(1):42-91844822
Cites: Pharmacogenetics. 1992 Oct;2(5):241-31306124
PubMed ID
7669487 View in PubMed
Less detail

Preparation and in-vivo pharmacokinetic study of a novel extended release compression coated tablets of fenoterol hydrobromide.

https://arctichealth.org/en/permalink/ahliterature92172
Source
AAPS PharmSciTech. 2008;9(3):1016-24
Publication Type
Article
Date
2008
Author
Elshafeey Ahmed H
Sami Elshaimaa I
Author Affiliation
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, El Kasr El Eini St., El Kasr El Eini, Cairo, Egypt. Ah_elshafeey@hotmail.com
Source
AAPS PharmSciTech. 2008;9(3):1016-24
Date
2008
Language
English
Publication Type
Article
Keywords
Animals
Chemistry, Pharmaceutical - methods - trends
Compressive Strength
Delayed-Action Preparations - chemical synthesis - pharmacokinetics
Diglycerides - chemistry
Dogs
Fenoterol - blood - chemical synthesis - pharmacokinetics
Male
Povidone - chemistry
Tablets, Enteric-Coated
Abstract
The aim of this study was to formulate extended release compression coated core tablets of fenoterol hydrobromide, a selective beta(2) adrenergic receptor agonist, in an attempt to prevent nocturnal asthma. Two hydrophilic polymers viz Kollidon SR, Polyox WSR 303 and a hydrophobic one (Precirol ATO5) were employed. Compression coated tablets were formulated by preparing a core tablet containing 7.5 mg drug and various amounts of polymer and Emcompress then compressed coated with the same polymeric materials. For comparison purpose different matrix tablets were also prepared employing the same polymers. In-vitro release studies were carried out at different pH (1.2 and 6.8). Pharmacokinetics of extended release tablets as well as commercially available immediate release tablets (Berotec) were studied after oral administration to beagle dogs using a new developed LC-MS/MS method with a lower limit of quantification of 1 ng/ml. Fenoterol release from compression coated tablets was significantly lower than matrix tablets. The mechanism of release was changed with the nature and content of polymer. The release pattern of drug from F16 containing 40 mg Kollidon SR divided in the core tablet (15 mg) and the rest in the compressed coat (25 mg) showed a typical zero order release kinetic that could extend drug release >10 h and reasonable time for 75% to be released (t(75)) (8.92 h). When compared to immediate release Berotec tablet the MRT was significantly extended from 7.03 +/- 0.76 to 10.93 +/- 1.25 h (P
PubMed ID
18770048 View in PubMed
Less detail

[Study of the process of tablet film coating on a fluidized bed using alcohol-chloroform solutions of hydroxypropylmethylcellulose]

https://arctichealth.org/en/permalink/ahliterature13287
Source
Farm Zh. 1975 Jan-Feb;(1):80-3
Publication Type
Article

[The value of compliance during chronic administration of acetylsalicylic acid in patients with acute coronary syndrome: results of the study FORPOST].

https://arctichealth.org/en/permalink/ahliterature119467
Source
Kardiologiia. 2012;52(9):22-8
Publication Type
Article
Date
2012
Author
A N Baglikov
V V Rafal'skii
Source
Kardiologiia. 2012;52(9):22-8
Date
2012
Language
Russian
Publication Type
Article
Keywords
Abdominal Pain - chemically induced
Acute Coronary Syndrome - epidemiology - prevention & control - psychology
Aged
Aspirin - administration & dosage - adverse effects
Drug-Related Side Effects and Adverse Reactions - prevention & control - psychology
Female
Hemorrhage - chemically induced
Humans
Male
Medication Adherence - psychology - statistics & numerical data
Middle Aged
Platelet Aggregation Inhibitors - administration & dosage - adverse effects
Questionnaires
Russia - epidemiology
Tablets, Enteric-Coated
Abstract
Found low compliance of admission to long-term acetylsalicylic acid (ASA) in patients with acute coronary syndrome (ACS): 74.9% of patients reported that the suspended or completely stopped taking the drug, and only 16.2% were fully committed to the long-term therapy with ASA. Patients are significantly more likely to discontinue conventional and buffered forms of ASA compared with intestinal-soluble forms of the drug (odds ratio - OR=1.81, 95% confidence interval - CI: 1.20 to 2.72; p=0,0027). The most common causes of low noncompliance were to receive ASA or the development of fear of adverse drug reactions (ADRs) - 47.1%, and the forgetfulness of the patients taking the drug regularly (25.4%). When receiving enteric forms of ASA NLR developed significantly less than in the case of buffered (OR 0.49, 95% CI, 0.35 to 0,69; p=0,00002) and "ordinary" (OR 0.21, 95 % CI 0.13 to 0,33; p=0,00001) forms of ASA. Compliance of the highest among all the drugs ASA, according to estimates by using a 10-point visual analog scale, were observed in enteric-coated forms of ASA (average score of 8.3+/-1.4). Some of the lowest noncompliance were noted to receive the "regular" aspirin tablet (6.9+/-1.4 points).
PubMed ID
23098543 View in PubMed
Less detail

9 records – page 1 of 1.